The Republic of Serbia applied the booster dose of the following COVID-19 vaccines: BNT162b2 mRNA (Pfizer-BioNTech), Sinopharm BBIBP-CorV (Vero Cell®), Gam-COVID-Vac (Sputnik V) and ChAdOk1 nCoV-19 (AstraZeneca). We aimed to examine the immunogenicity and reactogenicity of the booster dose and identify factors related to immune response and adverse events. Panel study, conducted during August and September 2021, included 300 persons receiving the booster dose at the Institute of Public Health of Serbia. Blood samples were taken on the day of receiving the booster dose, and after 7 and 28 days. When applying homologous regimen, the average increase in anti-spike immunoglobulin G was 8782.2 (after 7 days), 1213.9 after 28 days, while 9179.5 (after 7 days) and 16,728.1 after 28 days of heterologous regimen. Sinopharm BBIBP-CorV (p < 0.001) and Sputnik V (p < 0.001), age 65 and over (p = 0.001) and currently smoking (p < 0.001) were independently associated with lower levels of anti-spike immunoglobulin G. Female sex (OR = 1.77; 95%CI = 1.01–3.12), previous COVID-19 infection (OR = 3.62; 95%CI = 1.13–11.63) and adverse events after the second dose (OR = 2.66; 95%CI = 1.33–5.32) were independently associated with intense systemic adverse events 7 days after. Booster dose significantly increased antibodies titers, especially 28 days after heterologous regimen, without a significant increase in reactogenicity.
Type 2 diabetes is a major health burden to the society. Macrophages and liver inflammation emerged as important factors in its development. We investigated ultrastructural changes in the liver, with a special emphasis on macrophages in high fat diet (HFD) fed C57BL/6 J mice treated with metformin or simvastatin, two drugs that are used frequently in diabetes. Both metformin and simvastatin reduced the liver damage in HFD fed animals, manifested as the prevention of nonalcoholic steatohepatitis development and reduced activation and number of macrophages in the liver, as well as the percentage of these cells with lipid droplets in the cytoplasm compared to untreated HFD animals. In contrast with untreated HFD-fed animals, lipid droplets were not observed in lysosomes of macrophages in HFD animals treated with metformin and simvastatin. These findings provide new insight into the effects of metformin and simvastatin on the liver in this experimental model of type 2 diabetes and provide further rationale for implementation of statins in the therapeutic regimens in this disease.
18 February 2024 in Iranian Journal of Public Health
Background: Approximately 2.3 million female breast cancer cases were identified globally in 2020, resulting in 685,000 fatalities among women. Serbia too experiences a high breast cancer burden. Effective reduction of breast cancer incidence and mortality necessitates strategic measures encompassing the implementation of cost-effective screening technology. However, various impediments to screening implementation persist. We aimed to estimate the impact of socioeconomic factors on breast cancer screening in Serbia. Methods: Data from the 2019 National Health Survey of the population of Serbia was. The research was a descriptive, cross-sectional analytical study by design, on a representative sample of the population of Serbia. Data from women aged 15+ yr were used to examine the demographic and socioeconomic factors associated with breast cancer screening inequalities. Results: In Serbia the age group of women who predominantly participated in organized breast cancer screening (39.5%) were the ones aged 65+ yr. Women with a secondary education were 2.1x more likely to undergo a screening exam voluntarily (57.5%), compared to women with a higher education background (26.6%). When considering marital and financial circumstances, married/unmarried women from an affluent financial category exhibited a notably higher frequency of self-initiating a mammography (73% and 48.5%) in comparison to those financially struggling (27.6%). Conclusion: Strong support is imperative for countries to establish prevention and early detection programs for cancer.
Breast cancer (BC) is the most commonly diagnosed malignancy in female population. Mammography screening (sMG) is, as a public health intervention in the context of BC, considered a golden standard for its early detection within the population of asymptomatic women between 50 and 70 years of age. Organised BC programme (the Programme) was established in 2013 in the Republic of Serbia, marking the transition from the opportune to the population based screening model. The aim of this study was to analyse the data on the Programme implementation, to gain insight into the development and provision of its services in the Republic of Serbia, as well as the specific human and technical capacities required for its sustained delivery. Aggregated yearly reports of the Cancer screening office of the IPHS "Dr Milan Jovanovic Batut" were used as the primary data source. Between 2013 and 2023, a total of 445,261 screening mammography examinations were conducted in primary healthcare centres and mobile mammography units. During the observed period on average one third (30.1%) of performed sMGs within the Programme were conducted through the mobile mammography units, while an increasing trend of participating healthcare institutions as well as the human and technical capacities on the whole was noticed. The results of this analysis aim to serve as a basis for future, more comprehensive research, which would explore regional disparities in coverage and performance indicators for BC screening, with the purpose of updating data available to the wider academic community on the topic as well as the future improvements of the Programme.
Background: Breast cancer screening (BCS) by mammography was introduced globally in the last decades of the previous century and has been implemented in opportunistic or population-based models worldwide ever since. In Serbia, the national BCS Program was established in late 2012. Despite its existing framework, the Program's coverage remains suboptimal, and novel approaches to its optimization are being explored. The increasing use of artificial intelligence (AI) technology in numerous fields has been a hallmark of the previous decade, with AI-based solutions in breast imaging at the forefront of many research initiatives. Qualitative research has been previously conducted from Australia to Sweden, yielding insights into the AI-radiologist interaction, as well as the acceptability of screening-aged women toward AI use in screening. This study aims to gauge the stakeholders’ perspectives—radiologists’ and women's—on AI use in BCS in Serbia and help inform policy adaptations to maximize the prospective effectiveness of this public health intervention. Methods: Four focus groups (FGs) were organized in total, two with radiologists and two with screening-aged women, in Belgrade and Novi Sad. Residents in training and radiology specialists were divided for maximal discussion liberty. Two research members analyzed the discussion transcripts using a mixed inductive-deductive approach with a flexible coding frame. Results: Radiologists in this study see room for and have an overall cautiously positive attitude toward the application of AI in mammography BCS in the future. If AI were to perceptibly improve the current state of healthcare, such use of AI could be met with support among BCS-aged women. Conclusions: This study represents the first step towards understanding the attitudes of radiologists and screening-aged women in Serbia towards the use of AI in mammography. Additional studies will be necessary to get a more comprehensive overview.